Exact Mass: 474.0973
Exact Mass Matches: 474.0973
Found 34 metabolites which its exact mass value is equals to given mass value 474.0973,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
3-[({4-[4-({[1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulphanyl]propanoic acid
Rilmazafone
2-Amino-N-({1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-3-(dimethylcarbamoyl)-1H-1,2,4-triazol-5-yl}methyl)ethanimidate
Hyperxanthone|Hypholomin A|Hypholomin-A|Hypholomine A
Hyperxanthone|Hypholomin A|Hypholomin-A|Hypholomine A
Ki16425
3-[[[4-[4-[[[1-(2-chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazoly]phenyl]methyl]thio]-propanoic acid
Vandetanib
Vandetanib(ZD6474)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
Cys Cys Cys Phe
(2S)-2-[(2R)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanoic acid
Cys Cys Phe Cys
(2R)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanoic acid
Cys Phe Cys Cys
(2R)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid
Phe Cys Cys Cys
(2R)-2-[(2R)-2-[(2R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid
Rilmazafone
Rilmazafone
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic
Benzeneacetic acid, 4-chloro-a-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]benzo[b]thien-6-yl]oxy]-, methyl ester
Benzeneacetic acid, 4-chloro-a-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]benzo[b]thien-6-yl]oxy]-, methyl ester
METHYL3,4-DI[[(4-METHYLPHENYL)SULFONYL]AMINO]BENZOATE
METHYL3,4-DI[[(4-METHYLPHENYL)SULFONYL]AMINO]BENZOATE
6-Chloro-2-oxo-4-methylchromen-7-yl 4-O-beta-D-xylopyranosyl-beta-D-xylopyranoside
6-Chloro-2-oxo-4-methylchromen-7-yl 4-O-beta-D-xylopyranosyl-beta-D-xylopyranoside
N-(4-CHLORO-2-METHYLPHENYL)-2-(N-(3,4-DIMETHOXYPHENYL)PHENYLSULFONAMIDO)ACETAMIDE
N-(4-CHLORO-2-METHYLPHENYL)-2-(N-(3,4-DIMETHOXYPHENYL)PHENYLSULFONAMIDO)ACETAMIDE
5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide
5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide
3-[({4-[4-({[(1S)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
3-[({4-[4-({[(1S)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
3-[({4-[4-({[(1R)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
3-[({4-[4-({[(1R)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperidine-3-carboxamide
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperidine-3-carboxamide
GluN2B-NMDAR antagonist-1
GluN2B-NMDAR antagonist-1
GluN2B-NMDAR antagonist-1 is an orally active GluN2B-NMDAR antagonist. GluN2B-NMDAR antagonist-1 has neuroprotective activity. GluN2B-NMDAR antagonist-1 can be used for research of ischemic injury[1].
5,13,17,19-tetrahydroxy-15,22-dioxo-7-(2-oxopropyl)pentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁶,²¹]docosa-1(14),2,4(9),5,7,12,16,18,20-nonaene-6-carboxylic acid
5,13,17,19-tetrahydroxy-15,22-dioxo-7-(2-oxopropyl)pentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁶,²¹]docosa-1(14),2,4(9),5,7,12,16,18,20-nonaene-6-carboxylic acid
(1s,14r,24s)-3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione
(1s,14r,24s)-3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione
3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione
3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione
16-(2,4-dihydroxy-6-methylbenzoyl)-4,10-dihydroxy-6-methoxy-12-methyl-14-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,9(17),10,12-heptaene-8,15-dione
16-(2,4-dihydroxy-6-methylbenzoyl)-4,10-dihydroxy-6-methoxy-12-methyl-14-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,9(17),10,12-heptaene-8,15-dione
(1s,14r,24r)-3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione
(1s,14r,24r)-3,9,19,24-tetrahydroxy-11,17-dimethyl-6,22-dioxaheptacyclo[12.9.1.1¹,¹⁶.1⁴,⁸.0²,¹³.0¹²,²⁶.0²⁰,²⁵]hexacosa-2(13),3,8(26),9,11,16(25),17,19-octaene-7,15,21-trione
